AU2016257334B2 - Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy - Google Patents

Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy Download PDF

Info

Publication number
AU2016257334B2
AU2016257334B2 AU2016257334A AU2016257334A AU2016257334B2 AU 2016257334 B2 AU2016257334 B2 AU 2016257334B2 AU 2016257334 A AU2016257334 A AU 2016257334A AU 2016257334 A AU2016257334 A AU 2016257334A AU 2016257334 B2 AU2016257334 B2 AU 2016257334B2
Authority
AU
Australia
Prior art keywords
antibody
combination
cd16a
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016257334A
Other languages
English (en)
Other versions
AU2016257334A1 (en
Inventor
Stefan Knackmuss
Jens-Peter Marschner
Uwe Reusch
Martin Treder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15166303.6A external-priority patent/EP3091031A1/en
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of AU2016257334A1 publication Critical patent/AU2016257334A1/en
Application granted granted Critical
Publication of AU2016257334B2 publication Critical patent/AU2016257334B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016257334A 2015-05-04 2016-05-04 Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy Active AU2016257334B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15166303.6 2015-05-04
EP15166303.6A EP3091031A1 (en) 2015-05-04 2015-05-04 Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
EP16152650.4 2016-01-25
EP16152650 2016-01-25
PCT/EP2016/060113 WO2016177846A1 (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Publications (2)

Publication Number Publication Date
AU2016257334A1 AU2016257334A1 (en) 2017-11-09
AU2016257334B2 true AU2016257334B2 (en) 2021-08-12

Family

ID=56026814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016257334A Active AU2016257334B2 (en) 2015-05-04 2016-05-04 Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy

Country Status (20)

Country Link
US (1) US11167029B2 (enExample)
EP (1) EP3292153B1 (enExample)
JP (1) JP6609784B2 (enExample)
CN (1) CN107847587B (enExample)
AU (1) AU2016257334B2 (enExample)
BR (1) BR112017023579A2 (enExample)
CA (2) CA3219372A1 (enExample)
CY (1) CY1122283T1 (enExample)
DK (1) DK3292153T3 (enExample)
ES (1) ES2754557T3 (enExample)
HR (1) HRP20191933T1 (enExample)
HU (1) HUE045866T2 (enExample)
LT (1) LT3292153T (enExample)
PL (1) PL3292153T3 (enExample)
PT (1) PT3292153T (enExample)
RS (1) RS59489B1 (enExample)
RU (1) RU2761352C2 (enExample)
SI (1) SI3292153T1 (enExample)
SM (1) SMT201900598T1 (enExample)
WO (1) WO2016177846A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3052886A1 (en) 2017-02-28 2018-09-07 Affimed Gmbh Combination of an anti-cd16a antibody with a cytokine
CA3051062C (en) 2017-02-28 2023-09-26 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
KR102924742B1 (ko) * 2018-03-14 2026-02-10 아피메트 게엠베하 이중특이적 egfr/cd16 항원-결합 단백질
EP3774914A2 (en) * 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
RS65658B1 (sr) * 2018-08-27 2024-07-31 Affimed Gmbh Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
KR20220048988A (ko) * 2019-06-11 2022-04-20 마이얼로이드 테라퓨틱스, 인크. 대식세포 특이적 인게이저 조성물 및 이의 사용 방법
AU2020414409A1 (en) * 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
CA3209579A1 (en) * 2021-01-27 2022-08-04 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
US20240343811A1 (en) 2021-06-29 2024-10-17 Shandong Simcere Biopharmacutical Co., Ltd. Cd16 antibody and use thereof
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
JP2024542159A (ja) * 2021-11-04 2024-11-13 アーティバ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
CN116059348A (zh) * 2022-09-16 2023-05-05 四川大学华西医院 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
CN120077072A (zh) 2022-11-29 2025-05-30 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
CN121240884A (zh) 2023-04-05 2025-12-30 根马布股份公司 包含与cd30和cd3结合的抗体的药用组合物
CN117442721B (zh) * 2023-12-20 2024-03-15 苏州艾凯利元生物科技有限公司 一种包括nk细胞和nk细胞接合器分子的组合物
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
KR101510065B1 (ko) * 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UWE REUSCH ET AL, "A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30 + tumor cells", MABS, (2014-03-26), vol. 6, no. 3, doi:10.4161/mabs.28591, ISSN 1942-0870, pages 727 - 738 *

Also Published As

Publication number Publication date
CY1122283T1 (el) 2020-11-25
CA3219372A1 (en) 2016-11-10
JP2018514576A (ja) 2018-06-07
AU2016257334A1 (en) 2017-11-09
CN107847587B (zh) 2020-10-09
SI3292153T1 (sl) 2020-01-31
HRP20191933T1 (hr) 2020-01-10
BR112017023579A2 (pt) 2018-07-24
CA2983706C (en) 2024-01-02
HUE045866T2 (hu) 2020-01-28
HK1253022A1 (zh) 2019-06-06
DK3292153T3 (da) 2019-10-21
EP3292153A1 (en) 2018-03-14
EP3292153B1 (en) 2019-07-31
RU2017137251A3 (enExample) 2019-10-10
CA2983706A1 (en) 2016-11-10
LT3292153T (lt) 2019-11-11
PT3292153T (pt) 2019-11-05
RU2017137251A (ru) 2019-06-04
US20180085456A1 (en) 2018-03-29
JP6609784B2 (ja) 2019-11-27
RU2761352C2 (ru) 2021-12-07
WO2016177846A1 (en) 2016-11-10
CN107847587A (zh) 2018-03-27
PL3292153T3 (pl) 2020-02-28
ES2754557T3 (es) 2020-04-20
SMT201900598T1 (it) 2020-01-14
US11167029B2 (en) 2021-11-09
RS59489B1 (sr) 2019-12-31

Similar Documents

Publication Publication Date Title
US11167029B2 (en) Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
AU2014351308B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
US20250163152A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2015198312A1 (en) Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP2020525517A (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
AU2020231343B2 (en) IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
CN119095619A (zh) 抗cd19药剂的剂量方案及其用途
CN113728009A (zh) 双特异性CD123 x CD3双抗体在血液系统恶性肿瘤治疗中的给药方案
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
TW202615473A (zh) 包含抗免疫檢查點抗體或其片段和單鏈ｔｎｆｒｓｆ配體多聚體之結合蛋白
TW201713346A (zh) 調控免疫反應之方法及抗體
HK1253022B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)